The Northeast SAS Users Group Conference, a comprehensive program on SAS software programming and applications, will be held in Portland, Maine from September 11 to 14.
Portland, ME -- The Northeast SAS Users Group Conference, a comprehensive program on SAS software programming and applications, will be held in Portland, Maine from September 11 to 14. Conference content will include presentations and hands-on workshops in the following areas:
SAS experts will be available to help attendees solve programming problems, to demonstrate software features and to gather information on user needs for future software releases. Optional Pre-Conference Training Sessions and Sunday Workshops will provide additional in-depth learning opportunities. A Vendor Expo will be held in conjunction with the Conference.
According to Conference Co-Chair Lois Levin, "Attendees from past Conferences tell us the NESUG Conference is one of the best SAS training values available. They learn programming techniques and tips they can put to use right away on the job. And because our Conference offers such a wide variety of presentations and workshops there?s something for everyone, from the SAS newcomer to the experienced SAS programmer."
The NESUG 2005 Conference is open to all SAS users throughout the Northeast Region. SAS software is used extensively by the pharmaceutical industry and other industries that analyze large amounts of data.
Complete information on Conference content, location, special Conference hotel rates and registration is available online at www.nesug.org www.nesug.org/.
NESUG 2005 is sponsored in part by Westat, an employee-owned research corporation, Abt Associates, Inc., icrunchdata.com and SGI.
NESUG is an independent regional SAS user group serving the northeast from Canada to Washington, DC and west through New York and Pennsylvania. NESUG promotes the sharing of SAS-related information among members of the SAS community through this Annual Conference, a speaker sharing program and advocacy on behalf of SAS users to both SAS Institute and SUGI.
Final ENLIVEN Trial Results Confirm Long-Term Benefit of Turalio in Tenosynovial Giant Cell Tumor
July 9th 2025In final data from the Phase III ENLIVEN study, Turalio (pexidartinib) demonstrated durable tumor responses and a consistent safety profile in patients with symptomatic TGCT not amenable to surgery.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
Effect of AI/ML, Real World Evidence and Master Protocols on Trial Success
July 7th 2025How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.